Miranova (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and Levonorgestrel, the active ingredients in Miranova, are a combined oral contraceptive presented as tablets for oral use. They prevent pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus. GNH USA supplies Miranova as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miranova, a combined estrogen‑progestogen oral contraceptive, is indicated for prevention of pregnancy and related hormonal conditions.

Contraception: Prevents unintended pregnancy by suppressing ovulation and modifying cervical mucus. Menstrual cycle regulation: Provides scheduled withdrawal bleeding and reduces menstrual irregularities. Acne management: Improves acne symptoms in women when prescribed for this indication.

Miranova may cause a range of adverse reactions.

Common Side Effects: - Nausea or mild gastrointestinal upset. - Breast tenderness or enlargement. - Headache or migraine. - Spotting or breakthrough bleeding. - Mood changes or mild depression.

Serious or Rare Side Effects: - Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism). - Arterial thrombosis (stroke, myocardial infarction). - Severe hypertension. - Liver dysfunction or cholestasis. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before prescribing Miranova, clinicians should consider several safety aspects. - Contraindicated in women with a history of thromboembolic disorders: avoid use. - Avoid smoking in women over 35 years: increased cardiovascular risk. - Monitor blood pressure regularly: oral contraceptives may raise systolic/diastolic values. - Assess liver function: impaired metabolism can alter hormone levels. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Miranova can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive effectiveness. - Rifampin or other strong CYP3A4 inducers: may markedly lower hormone concentrations. - Certain antiretroviral protease inhibitors: can alter hormone metabolism.

Moderate Interactions (Monitor Closely): - Broad‑spectrum antibiotics such as ampicillin: may slightly diminish efficacy. - St. John’s wort: may lower plasma hormone levels. - Diuretics: can increase the risk of hypertension while on combined oral contraceptives.